Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF). The phase 3 Victor trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback